Managing ADC Toxicities

Anti Drug Conjugates represent a new way of treating thoracic, breast, and gastrointestinal cancers. Despite recent successes, many ADCs failed during clinical development due to excessive toxicities and unfavorable risk-benefit profiles. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ADCs and how clinicians can manage some of these toxicities.